Evidence map›Paper›PMID 32709976›Full record

ArticleCommunications biology2020

Author Correction: Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinoma.

Anne-Lise Peille, Vincent Vuaroqueaux, Swee-Seong Wong, Jason Ting, Kerstin Klingner, Bruno Zeitouni, Manuel Landesfeind, Woo Ho Kim, Hyuk-Joon Lee, Seong-Ho Kong and 9 more

Abstract readPublished Erratum
In one paragraph

Article in Communications biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Anne-Lise Peille *Charles River Discovery Research Services Germany GmbH (formerly Oncotest GmbH), Am Flughafen 12-14, 79108, Freiburg, Germany.
Vincent Vuaroqueaux *Charles River Discovery Research Services Germany GmbH (formerly Oncotest GmbH), Am Flughafen 12-14, 79108, Freiburg, Germany.ORCID http://orcid.org/0000-0001-9120-5332
Swee-Seong WongLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, 46285, USA.ORCID http://orcid.org/0000-0001-9956-4241
Jason TingLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Kerstin KlingnerCharles River Discovery Research Services Germany GmbH (formerly Oncotest GmbH), Am Flughafen 12-14, 79108, Freiburg, Germany.
Bruno ZeitouniCharles River Discovery Research Services Germany GmbH (formerly Oncotest GmbH), Am Flughafen 12-14, 79108, Freiburg, Germany.
Manuel LandesfeindCharles River Discovery Research Services Germany GmbH (formerly Oncotest GmbH), Am Flughafen 12-14, 79108, Freiburg, Germany.
Woo Ho KimDepartment of Pathology, Seoul National University College of Medicine, 101 Daehak-ro, Jongnogu, Seoul, Korea.ORCID http://orcid.org/0000-0003-0557-1016
Hyuk-Joon LeeDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, Korea.
Seong-Ho KongDepartment of Surgery, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul, Korea.
Isabella WulurLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Steven BrayLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Peter BronsertInstitute for Surgical Pathology, Medical Center-University of Freiburg, Freiburg, Germany.ORCID http://orcid.org/0000-0001-8558-0347
Nina ZanellaCharles River Discovery Research Services Germany GmbH (formerly Oncotest GmbH), Am Flughafen 12-14, 79108, Freiburg, Germany.
Greg DonohoLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Han-Kwang YangDepartment of Surgery and Cancer Research Institute, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, Korea.
Heinz-Herbert FiebigCharles River Discovery Research Services Germany GmbH (formerly Oncotest GmbH), Am Flughafen 12-14, 79108, Freiburg, Germany. fiebig@4hf.eu.ORCID http://orcid.org/0000-0001-6222-7321
Christoph ReinhardLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, 46285, USA. reinhard_christoph@lilly.com.
Amit AggarwalLilly Research Labs, Eli Lilly and Company, Indianapolis, IN, 46285, USA. aggarwal_amit@lilly.com.ORCID http://orcid.org/0000-0003-4800-4046

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID32709976
PMCPMC7381596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.